Marrow Therapeutics Launches With $173 Million For Bone Marrow-Targeted Medicines

Marrow Therapeutics has launched with $173 million in combined Series A and Series B funding to develop genetic medicines for severe blood and bone marrow disorders.

The company’s $53 million Series A round was co-led by Scion Life Sciences and venBio. OrbiMed led a subsequent $120 million Series B financing.

All Series A investors participated in the Series B alongside RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.

Scion Life Sciences founded Marrow Therapeutics, which is headquartered in Watertown, Massachusetts.

Developing A Bone Marrow-Targeting Platform

Marrow is developing engineered antibodies that target the transferrin receptor, also known as TfR1, in bone marrow.

The company’s Transferrin Antibody Bioconjugate platform is designed to deliver therapeutic payloads directly to bone marrow cells. Marrow plans to use this approach across multiple hematologic and bone marrow diseases.

Transferrin receptors help cells acquire iron and are present on multiple cell types. Developing medicines that engage the receptor requires controlling where therapeutic material is delivered and minimizing unintended effects in other tissues.

Marrow’s platform is intended to use engineered antibodies to reach bone marrow while avoiding off-target effects. The company is particularly focused on addressing the risk of anemia that has limited some earlier approaches involving TfR1.

Marrow believes its in vivo delivery strategy could overcome limitations associated with existing genetic medicines, including safety concerns, complex manufacturing, and restricted patient access.

These potential advantages have not yet been established in human clinical trials. The company’s programs remain in preclinical development.

Lead Program Targets Two Blood Disorders

Marrow’s lead candidate, MAR-101, is being developed for sickle cell disease and beta thalassemia.

The program is currently undergoing studies required to support an investigational new drug application.

MAR-101 is designed to decrease BCL11A and reactivate the production of fetal hemoglobin. BCL11A is a regulator involved in the transition from fetal to adult hemoglobin after birth.

Increasing fetal hemoglobin has become a validated therapeutic strategy for sickle cell disease and beta thalassemia. Fetal hemoglobin can reduce the effects of abnormal adult hemoglobin associated with these diseases.

Marrow intends to use one therapeutic approach for both conditions. The company refers to this strategy as a “pipeline in a product” because a single candidate could provide evidence supporting the delivery platform across more than one disease.

The program’s safety, durability, appropriate dose, and effectiveness will need to be evaluated through clinical studies.

Marrow is also developing additional programs for other blood and bone marrow disorders. The company has not disclosed detailed timelines or targets for those candidates.

Leadership With Transferrin Receptor Experience

Romesh Subramanian is leading Marrow as president and chief executive officer.

Tim Weeden has joined the company as chief scientific officer. His experience includes transferrin receptor biology, antibody development, and nucleic acid medicines.

John Najim is serving as chief operating officer and chief technology officer. His responsibilities include chemistry, manufacturing and controls, technical development, and business operations.

Gavriel Mullokandov is a founder and vice president of corporate development. He will support advancement of Marrow’s programs and broader platform.

The company’s leadership team has experience with earlier TfR1-based technologies that have entered clinical development. Marrow plans to apply lessons from those first-generation platforms to bone marrow delivery.

Adding Scientific And Industry Advisors

Art Levin has joined Marrow’s board of directors. Levin was the founding chief scientific officer of Avidity Biosciences and has experience developing genetic medicines.

Stuart Orkin has joined the company’s scientific advisory board. He is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and an investigator at Boston Children’s Hospital through the Howard Hughes Medical Institute.

Orkin’s research has contributed to scientific understanding of fetal hemoglobin regulation and blood disorders.

The board and scientific advisory appointments give Marrow additional experience in genetic medicine, hematology, and drug development as MAR-101 moves toward a potential clinical study.

The $173 million in financing will support the lead program, development of the Transferrin Antibody Bioconjugate platform, and advancement of additional candidates.

Marrow expects to move its programs toward the clinic during the coming year, although the timing will depend on preclinical results, manufacturing work, and regulatory review.

KEY QUOTES:

“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders – the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes. By precisely targeting the bone marrow, we’re able to deliver the potential of genetic medicines and provide sustained benefit, while simultaneously avoiding the risks that have constrained earlier approaches. Our preclinical data gives us tremendous confidence in this strategy, and we’re excited to move toward the clinic with a platform designed to address a broad range of severe hematological diseases.”

Romesh Subramanian, President and Chief Executive Officer of Marrow Therapeutics

“Marrow represents a differentiated technology platform, experienced leadership, and the potential to provide effective and safe treatment options for severe blood disorders. I am excited to work with this experienced team that has brought first-generation TfR1 platforms into the clinic. What is particularly compelling is their ‘pipeline in a product’ strategy. MAR-101 validates the platform across sickle cell disease and beta thalassemia with a single therapeutic approach, while their growing pipeline across additional blood and bone disorders demonstrates the true versatility and long-term value of this platform.”

Mona Ashiya, General Partner at OrbiMed

“From its inception, Marrow has had the potential to become a transformative and valuable company. This has been made possible by an experienced and knowledgeable leadership team that has consistently displayed the scientific rigor and operational excellence we look for at Scion. Marrow has optimized its proprietary bone marrow-targeting platform using lessons learned from validated first-generation TfR1 platforms targeting other tissues and organs. By leveraging well-understood biology, the company is in a great position to create paradigm-shifting therapies for patients dealing with severe blood disorders of high unmet need. We are truly excited to see Marrow advance its programs into the clinic in the coming year.”

Aaron Kantoff, Co-Founder and Managing Partner at Scion Life Sciences